Treating Telogen Effluvium

Expert Evaluation and Evidence-Based Management

Clumps of hair in the shower drain that weren’t there a few months ago. Handfuls coming out when you wash or brush. More than you’ve ever noticed on your pillow, on your clothing, in the sink. Sudden, alarming hair loss that appears to have no explanation is one of the most distressing experiences patients bring to a dermatology appointment, and for the majority of those patients, the underlying condition is telogen effluvium.

Telogen effluvium is the most common cause of diffuse hair loss, affecting millions of people each year. It develops when a physiological disruption, whether a significant illness, surgery, childbirth, severe nutritional deficiency, thyroid disease, or a period of intense psychological stress, triggers a mass shift of actively growing hairs into the resting phase of the hair cycle. Two to three months after that triggering event, those resting hairs shed simultaneously, producing the alarming volume of daily hair loss that drives most patients to seek evaluation. The good news, and the most important piece of information most patients receive too late, is that telogen effluvium is fully reversible in the overwhelming majority of cases when its cause is correctly identified and addressed.

At Connolly Dermatology, we provide expert evaluation and telogen effluvium treatment guided by evidence-based care. Our board-certified dermatologists identify the specific physiological trigger behind your hair loss, confirm the diagnosis through clinical examination, trichoscopy, and targeted laboratory testing, distinguish telogen effluvium from the other hair loss conditions it closely resembles, and build a management plan that addresses every correctable contributing factor while supporting the fastest possible full recovery. Understanding the cause of your hair loss is the essential first step, and getting that answer from a dermatologist produces dramatically better outcomes than self-managing months of shedding without a clear direction.

If you are experiencing diffuse shedding that concerns you, scheduling an evaluation provides the specific answers your hair and scalp deserve. Have your hair loss assessed by the specialists at Connolly Dermatology and get the clarity you need to move forward confidently.

Understanding Telogen Effluvium

The Hair Cycle, What Disrupts It, and Why the Shedding Happens When It Does

To understand telogen effluvium, it helps to understand the hair growth cycle that it disrupts. Each hair follicle on the scalp independently cycles through three phases. The anagen phase is the active growth phase, during which the hair shaft is produced and lengthened. It lasts between two and seven years in scalp follicles. The catagen phase is a brief transitional period of two to three weeks during which the follicle detaches from the dermal papilla and prepares to rest. The telogen phase is the resting phase, lasting approximately three to four months, during which the hair shaft is retained in the follicle as a club-shaped structure but no active growth occurs. At the end of telogen, the old hair is shed as a new anagen hair begins to form and push it out. Under normal circumstances, approximately 5 to 15 percent of scalp hairs are in the telogen phase at any given time, producing a normal baseline daily shedding of approximately 50 to 100 hairs.

Telogen effluvium occurs when a significant physiological or psychological stressor triggers a large proportion of actively growing anagen hairs to prematurely shift into the telogen resting phase all at once. The critical detail is the timing: this premature shift happens at the time of the triggering event, but the shedding does not begin until those hairs reach the end of their telogen phase and are expelled, which takes the standard three to four months. This is why patients typically experience the peak of their shedding two to three months after whatever caused it, and why so many patients cannot initially connect their hair loss to an event that happened weeks or months earlier. Identifying that triggering event from the history, looking back three months from the onset of shedding, is the central diagnostic task of telogen effluvium evaluation.

Acute Telogen Effluvium

Acute telogen effluvium is the most common form. It follows a single identifiable triggering event and typically runs its course within three to six months from the onset of shedding, after which follicles re-enter anagen and density progressively recovers over the following six to twelve months. The shedding can be dramatic, with patients losing several hundred hairs per day at its peak, but because the follicles are structurally intact and undamaged, full recovery is the expected outcome once the trigger is resolved. Common triggers include major surgery, serious physical illness, high fever, COVID-19 infection, childbirth, significant psychological stress, sudden severe dietary restriction, and rapid weight loss. In most patients with acute telogen effluvium, the trigger is identifiable through careful history-taking.

Postpartum Telogen Effluvium

Postpartum telogen effluvium deserves specific mention because it is the most common form of telogen effluvium in women of reproductive age and one of the most alarming presentations for patients who are not warned to expect it. During pregnancy, high circulating estrogen levels prolong the anagen phase across the majority of scalp follicles, producing the characteristically thicker, more lustrous hair that many pregnant women notice. After delivery, estrogen levels drop precipitously, and the follicles that have been held in extended anagen synchronously enter telogen. Two to three months after delivery, typically beginning between 1 and 5 months postpartum, these follicles shed in large numbers, producing sudden, dramatic diffuse hair loss that can be profoundly distressing to new parents who did not expect it. Postpartum telogen effluvium is entirely self-limiting, typically resolving within 6 to 12 months. If it persists beyond this timeframe or if the degree of density reduction is greater than expected, evaluation to identify concurrent iron deficiency, thyroid dysfunction, or unmasked androgenetic alopecia is indicated.

Chronic Telogen Effluvium

Chronic telogen effluvium is defined as persistent diffuse shedding lasting more than six months. Unlike acute telogen effluvium, it often lacks a single clear precipitating event and may fluctuate in severity over months to years. It predominantly affects women between 30 and 60 years of age who have a full, dense head of hair, and the shedding, while diffuse and persistent, rarely produces the dramatic baldness of androgenetic alopecia or the patchy loss of alopecia areata. The cause is frequently multifactorial, involving low-grade ongoing stressors, subclinical nutritional deficiencies, hormonal fluctuations, or a combination that collectively keeps the hair cycle from restoring its normal balance. Identifying and addressing every contributing factor, even those that individually appear minor, is the management strategy that produces eventual resolution. Chronic telogen effluvium can, despite its alarming persistence, be fully distinguished from scarring or irreversible forms of hair loss and has an excellent long-term prognosis with appropriate evaluation and management.

Telogen Effluvium vs. Other Hair Loss Conditions

Several hair loss conditions produce diffuse shedding that can be mistaken for telogen effluvium, and telogen effluvium itself may coexist with or unmask another condition. The comparison below highlights key distinguishing features that guide the diagnostic evaluation.

These distinctions guide every element of clinical decision-making. Telogen effluvium and androgenetic alopecia frequently coexist, with a triggering event unmasking or accelerating a pre-existing androgenetic alopecia that becomes apparent as the TE resolves. Identifying both components when present ensures that the TE component and the androgenetic component are each addressed appropriately.

Is Telogen Effluvium Dangerous?

Telogen effluvium itself is not dangerous. The follicles are structurally intact throughout the process. No follicles are destroyed. No scarring occurs. The condition does not become cancerous and does not indicate any skin disease. In the overwhelming majority of patients, it resolves completely with time and trigger correction.

What makes professional evaluation genuinely important, beyond the reassurance it provides, is that telogen effluvium is frequently the visible sign of a systemic condition that does require medical attention. Iron deficiency severe enough to drive telogen effluvium may indicate gastrointestinal blood loss, malabsorption, or nutritional inadequacy that warrants further investigation. Thyroid disease identified through hair loss workup can be treated before it produces more significant systemic consequences. Postpartum thyroiditis, which peaks between 1 and 4 months after delivery and closely mimics postpartum telogen effluvium in timing, requires specific management. Nutritional deficiencies from undiagnosed eating disorders or post-bariatric surgery malabsorption represent systemic issues that extend beyond hair loss. The psychological dimension is also clinically real: the combination of an unexpected, dramatic change in appearance and uncertainty about whether the shedding will stop produces significant anxiety in many patients. Accurate diagnosis and a clear prognosis, both provided by a thorough dermatologic evaluation, reduce this anxiety substantially and have direct positive effects on patient wellbeing.

Signs and Symptoms of Telogen Effluvium

Telogen effluvium has a recognizable constellation of signs and symptoms once you know what to look for. Understanding these features helps patients recognize the condition, communicate precisely with their dermatologist, and distinguish what they are experiencing from other forms of hair loss that have different implications and management approaches.

Diffuse, Generalized Shedding

The defining feature of telogen effluvium is diffuse hair loss affecting the entire scalp equally, without the preferential patterning of androgenetic alopecia or the distinct patches of alopecia areata. Hairs are lost from all regions of the scalp, front to back and side to side, producing a uniform reduction in overall density rather than concentrated thinning at any specific zone. Patients typically notice more hair than usual on their pillow in the morning, in the shower drain after washing, on their brush or comb, on their clothing, and in their hands when running fingers through their hair. The volume increase can be dramatic; some patients lose several hundred hairs per day at the peak of shedding, compared to a normal baseline of 50 to 100.

The Two-to-Three Month Delay

One of the most diagnostically useful features of telogen effluvium is also the most counterintuitive: the shedding begins two to three months after the triggering event, not at the time of the trigger. A patient who had major surgery in January will typically begin experiencing significant shedding in March or April. A patient who gave birth in September will typically notice shedding beginning in November or December. A patient who went through a significant period of extreme stress in May will typically begin shedding in July or August. Because patients are understandably focused on the current shedding rather than what happened several months ago, this temporal relationship is frequently missed without careful history exploration. When a patient cannot initially identify a trigger, asking specifically about events that occurred two to four months before shedding began almost always reveals the cause.

Club-Shaped Hair Roots

When hairs shed in telogen effluvium, they are in the telogen resting phase and have a characteristic white, club-shaped bulb at the root end. This is the telogen club, the fully keratinized root structure of a resting hair. Examining shed hairs under magnification confirms telogen roots and distinguishes telogen shedding from anagen effluvium, in which hairs fracture mid-shaft or have a tapered, unpigmented anagen root structure without the club morphology. Most patients with telogen effluvium can observe the white bulbs at the roots of their shed hairs with the naked eye or a simple magnifying glass, and this finding is reassuring because club-rooted hairs are the normal end-of-cycle hairs that should have shed eventually anyway; they are simply doing so en masse rather than individually.

Normal Scalp Appearance

Despite the dramatic shedding, the scalp in telogen effluvium looks and feels entirely normal. There is no erythema, no scaling, no pustules, no scarring, and no follicular disturbance visible to the naked eye or on trichoscopy beyond the predominance of telogen hairs. This is in direct contrast to scarring alopecias, where the scalp shows active inflammation and eventual atrophic scarring, and to active alopecia areata, where distinctive trichoscopic features are visible. A normal scalp appearance combined with diffuse generalized shedding is a clinically reassuring combination that points toward a reversible process.

Reduced Hair Volume Rather Than Visible Balding

Most patients with telogen effluvium experience a subjective and objective reduction in overall hair volume, the ponytail feels thinner, the bun requires more wraps, the hair looks less full in mirrors, rather than visible bald patches or empty scalp. Visible scalp thinning can occur in severe or prolonged cases, particularly over the crown and temples where hair density normally provides the greatest visual coverage, but true balding with exposed scalp is uncommon in telogen effluvium and, when present, should prompt evaluation for concurrent androgenetic alopecia. The absence of visible baldness, combined with the dramatic shedding, is one of the features that distinguishes telogen effluvium from other forms of hair loss.

Scalp Sensitivity or Tenderness

Some patients with acute telogen effluvium, particularly those in the early active phase, report scalp tenderness or sensitivity, a sensation sometimes described as the scalp feeling sore, prickling, or tender to the touch. This is thought to reflect the neural changes associated with the mass synchronous follicular activity that accompanies the shift from anagen to telogen. The symptom is not universal but is recognized and does not indicate a serious complication.

Signs That Warrant Evaluation

You should see a dermatologist about hair shedding if:

•       You are shedding significantly more hair than usual and are concerned, regardless of duration
•       Shedding has persisted for more than 2 months without slowing
•       The shedding began after a recognized stressful event, illness, surgery, or change in your health status
•       You are 2 to 4 months postpartum and experiencing significant hair loss
•       Shedding is accompanied by fatigue, cold intolerance, weight change, or other symptoms that suggest thyroid dysfunction or nutritional deficiency
•       You have recently started or stopped a medication and noticed subsequent hair loss
•       Shedding has been present for more than 6 months without any signs of slowing or recovery
•       You cannot identify any trigger and are uncertain whether your shedding is telogen effluvium or another condition
•       The hair loss is causing significant anxiety or distress regardless of its severity

Triggers and Risk Factors for Telogen Effluvium

Telogen effluvium is a response to physiological disruption, not a disease with a fixed intrinsic cause. Identifying the specific trigger in each patient is the cornerstone of management, because the trigger is usually the only thing that needs to be addressed for the hair cycle to restore itself. The following represents the full clinical spectrum of recognized triggers and contributing factors.

Physical Stress and Illness

Major physical stressors are among the most common and most reliably identified triggers for acute telogen effluvium. Major surgery, particularly procedures requiring general anesthesia or significant physiological stress, produces telogen effluvium in a substantial proportion of patients regardless of the surgery type. Serious illness with high fever, hospitalization-level illness, significant blood loss, and organ system insults all produce the physiological disruption that shifts follicles into telogen. COVID-19 infection emerged as a prominent trigger during the pandemic, producing significant post-COVID telogen effluvium in a large proportion of individuals who experienced moderate to severe illness. Chronic systemic illnesses including autoimmune conditions, inflammatory bowel disease, chronic infections, and malignancy can produce ongoing or recurrent telogen effluvium through sustained physiological stress.

Childbirth and Postpartum

Postpartum hair loss is one of the most common presentations of telogen effluvium and affects a significant proportion of new parents. The mechanism is the sudden withdrawal of the high-estrogen environment of pregnancy, which had been sustaining an abnormally large proportion of follicles in extended anagen. This is classified as delayed anagen release, a distinct physiological subtype in which prolonged anagen maintenance is followed by synchronous telogen entry when the sustaining hormonal signal withdraws. The resulting shedding, dramatic in many patients, typically begins 1 to 5 months after delivery and resolves within 6 to 12 months. Iron deficiency from peripartum blood loss frequently compounds the postpartum trigger and significantly extends the recovery timeline when it is not identified and corrected.

Nutritional Deficiencies

Nutritional deficiencies are the most important and most treatable contributors to telogen effluvium, and they are among the most frequently missed because patients and non-specialist clinicians often check hemoglobin or complete blood count rather than the more sensitive markers that actually reflect hair-relevant nutritional status.

Iron deficiency is the most common nutritional trigger of telogen effluvium in women. Serum ferritin, not hemoglobin alone, is the critical measurement. Ferritin levels below 30 ng/mL are clearly associated with increased hair shedding in multiple published studies, and levels between 30 and 70 ng/mL may be suboptimal for follicular cycling even in the absence of frank anemia. Many patients with iron-deficiency-driven telogen effluvium have normal hemoglobin and complete blood counts but significantly low ferritin, which is why a hemoglobin-only assessment misses the diagnosis.

Zinc deficiency impairs the rapidly dividing cells of the hair matrix and produces hair fragility and increased shedding. Protein deficiency, whether from crash dieting, severe caloric restriction, eating disorders, post-bariatric surgery malabsorption, or prolonged illness, deprives follicular cells of the building blocks needed for hair shaft production and reduces the ability to sustain active anagen cycling. Vitamin D deficiency has been associated with hair loss in multiple studies, with receptors for active vitamin D present in the hair follicle playing a role in follicular cycling. Niacin (vitamin B3) deficiency, though less common, produces significant hair loss and responds dramatically to correction.

Thyroid Disease

Thyroid disease, including both hypothyroidism and hyperthyroidism, is a significant and treatable cause of diffuse hair loss. Thyroid hormones regulate the metabolic activity of virtually all body cells, including hair matrix cells, and thyroid dysfunction impairs normal follicular cycling. Hypothyroidism is the more common and more consistently associated form; the hair loss typically develops gradually as thyroid hormone levels decline and may be accompanied by dry, coarse hair texture, fatigue, cold intolerance, weight gain, constipation, and bradycardia. Postpartum thyroiditis, an autoimmune thyroid condition that peaks between 1 and 4 months after delivery, produces hair loss with the same timing as postpartum telogen effluvium and requires specific diagnosis and management beyond the reassurance appropriate for physiological postpartum shedding.

Psychological Stress

Significant psychological stress, including grief, bereavement, divorce, serious relationship conflict, job loss, financial crisis, and prolonged anxiety or depression, is a well-established trigger for telogen effluvium. The mechanism involves activation of the hypothalamic-pituitary-adrenal axis and sympathetic nervous system, with stress-related neuropeptides and cortisol altering follicular cycling and accelerating the anagen-to-telogen transition. Patients who have experienced major life stressors frequently do not spontaneously connect these events to hair loss that begins months later, and directed questioning about the period 2 to 4 months before shedding began is consistently more productive than asking patients to identify their trigger without that temporal framing.

Medications

A clinically important and frequently overlooked category of telogen effluvium triggers. The medications most consistently associated with telogen effluvium include anticoagulants (both heparin and warfarin produce dose-dependent telogen effluvium in a proportion of users), beta-blockers (propranolol, metoprolol, atenolol), ACE inhibitors, oral retinoids (isotretinoin produces dose-dependent telogen effluvium through its effect on follicular retinoid receptors), antidepressants (particularly SSRIs and venlafaxine in some patients), mood stabilizers (lithium and valproate are the most commonly implicated), antiepileptics (valproate and carbamazepine), antithyroid medications, hormonal contraceptives (particularly progestin-dominant preparations), and some cholesterol-lowering medications. The temporal relationship between medication initiation and shedding onset, typically 2 to 3 months, is the key diagnostic feature. The complete medication list, including all over-the-counter medications, supplements, and herbal preparations, is an essential component of the telogen effluvium history.

Rapid Weight Loss and Dietary Restriction

Rapid weight loss of any cause, including voluntary caloric restriction, crash dieting, weight loss surgery, and weight loss related to illness, triggers telogen effluvium through a combination of caloric and protein insufficiency, micronutrient depletion, and physiological stress. Post-bariatric surgery patients are at particularly high risk because the combination of surgical stress, caloric restriction during the rapid weight loss phase, and potential malabsorption of iron, zinc, and other micronutrients creates multiple simultaneous telogen effluvium triggers. Hair loss following bariatric surgery typically begins 3 to 4 months postoperatively and can be severe, but it is substantially mitigated by proactive nutritional supplementation protocols implemented before and after surgery.

Can Telogen Effluvium Be Prevented?

Most episodes of acute telogen effluvium cannot be fully prevented because the triggering events, including illness, surgery, childbirth, and unavoidable life stressors, are not preventable. However, certain strategies meaningfully reduce the severity and duration of shedding when a trigger event is anticipated or recognized.

Optimize Nutritional Status Proactively

Patients who know they will undergo major surgery, women approaching delivery, and patients with chronic illness should have ferritin, zinc, and vitamin D levels assessed and corrected proactively. Post-bariatric surgery patients benefit enormously from pre-operative nutritional optimization and well-designed post-operative supplementation protocols. Iron supplementation begun before delivery in patients with borderline ferritin levels significantly reduces postpartum shedding severity.

Correct Thyroid Disease Before Additional Triggers Accumulate

Patients with known thyroid disease should maintain consistent treatment and monitoring to prevent subclinical hypothyroidism from becoming an additional telogen effluvium trigger. Postpartum thyroid status should be monitored in patients with known thyroid autoantibodies or prior thyroid history.

Maintain Adequate Protein and Caloric Intake During Illness

During periods of significant illness or hospitalization, protein and caloric adequacy supports follicular cycling and reduces the severity of physiologically driven telogen effluvium. This is a contributor that clinicians can address in hospitalized patients through attention to nutritional support.

Address Modifiable Medication Triggers

When a medication is identified as likely driving telogen effluvium, discussing alternatives with the prescribing physician may reduce or eliminate the hair loss trigger without compromising the therapeutic goal the medication was prescribed to achieve.

Diagnosis and Evaluation of Telogen Effluvium

Telogen effluvium is diagnosed through the integration of a detailed clinical history, physical examination findings, trichoscopy, and targeted laboratory evaluation. No single test confirms the diagnosis in isolation. The clinical picture, assembled from history, examination, and laboratory results, produces a confident diagnostic conclusion in the majority of cases. When the diagnosis remains uncertain, scalp biopsy provides histopathologic confirmation. The diagnostic process at Connolly Dermatology is designed to answer two questions with equal rigor: Is this telogen effluvium? And if so, what is causing it?

Detailed Clinical History: The Most Diagnostic Tool Available

The single most diagnostically productive step in telogen effluvium evaluation is a thorough, timeline-oriented history. Your dermatologist works through your recent health history systematically, focusing specifically on events occurring 2 to 4 months before your shedding began. This includes any illnesses, medical procedures, changes in medications, significant life stressors, dietary changes, weight changes, reproductive events, and changes in general health or energy. The complete current and recent medication list is reviewed. Dietary patterns, including evidence of restrictive eating, bariatric surgery, recent significant weight loss, or known avoidance of food groups providing key nutrients, are explored. Menstrual and obstetric history is documented in women. Symptoms that might indicate thyroid disease or other systemic conditions, including fatigue, cold intolerance, heat intolerance, weight change, heart palpitations, bowel changes, and dry skin, are assessed. Family history of hair loss on both sides is recorded to evaluate the likelihood of coexisting androgenetic alopecia.

Physical Examination and Hair Pull Test

The scalp is examined across all regions. In telogen effluvium, the scalp typically appears normal, with no inflammation, scaling, erythema, or follicular disturbance. Hair density is assessed clinically across the frontal, parietal, vertex, and occipital regions to determine whether loss is diffuse and uniform or shows any patterned preferential distribution that might indicate coexisting androgenetic alopecia. The hair pull test is the most immediately informative bedside assessment for active shedding. The examiner grasps approximately 60 hairs between the thumb and index finger across multiple scalp regions and applies firm, smooth traction. A yield of more than 6 hairs per pull is considered positive for active effluvium. In telogen effluvium, the pull test is strongly positive across all scalp regions, including the occipital area, which distinguishes it from androgenetic alopecia, where the pull test is usually negative at the back of the scalp. The shed hairs are examined for their root structure; club-shaped, white telogen roots confirm active telogen shedding.

Trichoscopy

Trichoscopy provides magnified visualization of scalp and hair shaft features that complement and extend the clinical examination. In telogen effluvium, trichoscopy reveals a predominance of single-hair follicular units without the miniaturized vellus hairs, hair diameter variability, or peripilar sign that characterize androgenetic alopecia. The terminal-to-vellus ratio remains normal. The scalp surface shows no perifollicular scale, no follicular dropout, and no scarring. This normal trichoscopic pattern, in the clinical context of diffuse shedding and a positive pull test, strongly supports the telogen effluvium diagnosis. Trichoscopy also identifies any concurrent features of androgenetic alopecia or alopecia areata that may be contributing alongside the telogen effluvium component.

Targeted Laboratory Studies

Laboratory evaluation is an essential and non-optional component of telogen effluvium assessment because it identifies the specific correctable causes that determine the treatment plan. The standard evaluation includes a complete blood count with differential, comprehensive metabolic panel, thyroid-stimulating hormone, free T4, serum ferritin (the critical iron status marker for hair loss, not hemoglobin alone), serum iron and total iron-binding capacity (to calculate transferrin saturation), zinc, vitamin D 25-OH, and vitamin B12. In women with menstrual irregularity or signs of androgen excess, free and total testosterone, DHEA-S, and prolactin are added. In patients with recent childbirth, thyroid peroxidase and antithyroglobulin antibodies are assessed to screen for postpartum thyroiditis. Antinuclear antibody testing is appropriate when lupus-associated hair loss cannot be excluded. RPR (rapid plasma reagin) for syphilis screening is obtained when the clinical picture includes risk factors or features inconsistent with straightforward telogen effluvium.

Ferritin deserves specific emphasis: it is the most commonly deficient laboratory value identified in women with telogen effluvium, it is the most commonly under-tested because providers frequently check hemoglobin or CBC without ferritin, and it is the single laboratory correction that most reliably accelerates recovery when identified and treated. A normal hemoglobin does not exclude iron deficiency as a contributor to hair loss. Serum ferritin must be measured specifically, and the target for hair loss recovery is generally accepted as greater than 70 ng/mL, which is considerably higher than the lower limit of normal on most laboratory reference ranges.

Scalp Biopsy

Scalp biopsy is not required for typical telogen effluvium presentations where the history, examination, trichoscopy, and laboratory findings produce a confident diagnosis. It is indicated when the diagnosis remains uncertain after full evaluation, when a concurrent or alternative diagnosis such as androgenetic alopecia, alopecia areata, or a scarring alopecia cannot be excluded, or when chronic telogen effluvium has persisted without a clearly identified cause and a more comprehensive tissue assessment is warranted. A 4-millimeter punch biopsy sectioned horizontally shows an increased proportion of telogen and catagen follicles, typically exceeding 25 percent of follicles counted, with a normal terminal-to-vellus ratio that distinguishes it from androgenetic alopecia. The absence of peribulbar lymphocytic inflammation excludes alopecia areata, and the absence of follicular fibrosis and scarring excludes cicatricial alopecias.

When Should You Get Telogen Effluvium Evaluated?

You should see a dermatologist if you notice:

•       Significantly increased hair shedding that concerns you, at any point after it begins
•       Shedding that began 2 to 3 months after a significant illness, surgery, stressful event, or dietary change
•       Significant shedding beginning 1 to 5 months postpartum
•       Diffuse shedding accompanied by fatigue, cold intolerance, weight change, or other systemic symptoms
•       Shedding that has persisted for more than 3 months without slowing
•       Shedding that began after starting a new medication
•       Hair loss that you cannot confidently identify as telogen effluvium rather than another type
•       Any shedding causing significant anxiety or affecting your daily quality of life

Accurate diagnosis and identification of the specific cause gives you a clear prognosis, a specific treatment plan, and the evidence-based reassurance that most patients with telogen effluvium need most urgently.

Telogen Effluvium Treatment Options

The most important treatment for telogen effluvium is identifying and correcting the cause. In cases where the trigger is physiological and time-limited, such as postpartum shedding or post-surgical effluvium with adequate nutritional status, the primary management is accurate reassurance about the timeline and prognosis. In cases where a correctable cause is identified, whether nutritional deficiency, thyroid disease, medication trigger, or inadequate dietary intake, specific targeted treatment produces the fastest recovery. The following represents the complete management approach at Connolly Dermatology.

Trigger Identification and Correction: The Primary Treatment

Correcting the identified cause of telogen effluvium is the single most effective treatment available and the one that produces the most reliable full recovery. When the trigger is time-limited and already resolved, such as a post-surgical effluvium from a surgery that occurred two to three months ago, management is primarily reassurance and monitoring with specific nutritional correction if indicated. When the trigger is ongoing and correctable, targeted intervention is both possible and essential. The completeness and speed of recovery correlate directly with how thoroughly the contributing factors are identified and addressed.

Iron and Ferritin Repletion

Iron deficiency identified on laboratory evaluation is corrected with oral iron supplementation, typically ferrous sulfate 325 mg (containing 65 mg elemental iron) taken once to twice daily. The frequency and formulation are adjusted based on tolerability, as gastrointestinal side effects, including constipation and nausea, are common at standard doses. Taking iron with vitamin C (ascorbic acid) enhances absorption. Taking iron away from meals, coffee, tea, calcium, and antacids improves absorption by reducing competing inhibitors. Ferritin levels are rechecked after 3 to 4 months of supplementation to confirm rising levels, and supplementation continues until ferritin reaches the target of at least 70 ng/mL. Patients typically notice a reduction in shedding and beginning of hair recovery within 3 to 6 months of achieving adequate ferritin levels. When oral iron is poorly tolerated or poorly absorbed, intravenous iron infusion produces rapid and reliable ferritin repletion and can significantly accelerate hair recovery in patients with severe deficiency or malabsorption.

Thyroid Treatment

Thyroid disease identified on laboratory evaluation is treated in coordination with the patient’s primary care physician or endocrinologist. Hypothyroidism is treated with levothyroxine titrated to achieve a TSH within the normal range. Hyperthyroidism is managed with appropriate antithyroid therapy. Hair recovery typically follows thyroid normalization over 3 to 6 months, reaching full recovery within 6 to 12 months after a stable euthyroid state is achieved. Postpartum thyroiditis may be transient, requiring monitoring and short-term management, or may progress to permanent hypothyroidism requiring ongoing levothyroxine therapy.

Nutritional Optimization

Beyond iron, all identified nutritional deficiencies are corrected through a combination of dietary improvement and targeted supplementation. Zinc deficiency is corrected with zinc supplementation at 40 to 50 mg elemental zinc daily. Vitamin D insufficiency is corrected with vitamin D3 supplementation at doses tailored to the baseline level and target. Protein intake is assessed and dietary counseling provided for patients with inadequate protein consumption, emphasizing the importance of adequate protein intake from whole food sources for follicular recovery. In post-bariatric surgery patients, a comprehensive micronutrient supplementation protocol is implemented and monitored with regular laboratory surveillance. The goal is not to supplement indiscriminately but to correct specifically identified deficiencies to evidence-based target levels while optimizing overall dietary adequacy.

Medication Review and Adjustment

When a medication is identified as a probable trigger, its discontinuation or substitution is discussed with the prescribing physician. Decisions are made collaboratively, weighing the importance of the medication’s therapeutic purpose against the hair loss burden. In many cases, a therapeutic equivalent with a lower hair loss risk profile can be substituted. When no suitable alternative exists, the decision to continue the medication is made with clear patient understanding of the expected timeline and the reassurance that shedding will generally improve with time even if the medication must continue.

Minoxidil as a Bridge Therapy

Topical or oral minoxidil is used as a bridge treatment to support and accelerate hair recovery during the period of trigger correction and follicular re-entry into anagen. By prolonging the anagen phase and increasing blood flow to the follicular dermal papilla, minoxidil reduces the duration and subjective severity of the shedding period, accelerates visible density recovery, and is particularly valuable when telogen effluvium is prolonged, when a concurrent androgenetic alopecia component is identified, or when the patient’s distress level warrants active pharmacological support during recovery. Low-dose oral minoxidil at 0.625 to 2.5 mg daily in women and topical 5% solution or foam applied to the scalp are both effective adjunctive options. Patients are counseled that an initial increase in shedding in the first 4 to 8 weeks of minoxidil use is expected and reflects the transition of telogen hairs as new anagen growth begins; this initial shed, though temporarily alarming, actually signals that the treatment is working.

Reassurance, Education, and Psychological Support

For patients with acute telogen effluvium where the trigger is identified and time-limited, evidence-based reassurance about the expected recovery timeline is itself a primary management intervention. The vast majority of patients with acute telogen effluvium achieve complete or near-complete hair recovery within 6 to 12 months of trigger correction. Communicating this prognosis clearly, explaining the biological mechanism in patient-friendly terms, and providing a realistic month-by-month recovery expectation dramatically reduces the anxiety that dramatically worsens subjective distress during the shedding period. Patients who understand that their shedding will slow, stop, and reverse are far better equipped to manage the recovery period than those left without clear prognostic information. For patients with chronic telogen effluvium where the course is more variable, honest communication about the characteristically benign long-term outcome despite the frustratingly prolonged course provides the same psychological benefit.

Platelet-Rich Plasma (PRP) Therapy

For patients with prolonged telogen effluvium, chronic telogen effluvium, or telogen effluvium with a concurrent androgenetic alopecia component that has been identified, platelet-rich plasma therapy delivers concentrated growth factors including platelet-derived growth factor, vascular endothelial growth factor, and insulin-like growth factor-1 directly to scalp follicles, supporting follicular re-entry into anagen and accelerating density recovery. PRP is an adjunctive treatment that complements primary trigger correction and nutritional optimization. A standard series of three to four monthly injections followed by maintenance is the typical protocol, and results are most reliable when the primary cause of shedding is simultaneously being addressed.

Why Choose Connolly Dermatology for Telogen Effluvium Treatment

Care Guided by Experience and Clinical Judgment

The most common frustration patients with telogen effluvium bring to Connolly Dermatology is that their prior evaluation, whether in a primary care setting or an urgent care visit, concluded without a specific cause, without ferritin testing, and without a clear prognosis. “It’s stress” or “it will grow back” without specific investigation and targeted intervention leaves patients without the information they need to actually support their recovery. Our evaluation is systematically comprehensive in exactly the ways that matter most for telogen effluvium outcomes.

Board-Certified Dermatologists

Our dermatologists are trained in the complete evaluation and management of all hair loss types, with the clinical skill to distinguish telogen effluvium from androgenetic alopecia, alopecia areata, and the other conditions it resembles, and to identify the specific triggers and contributing factors in each patient’s presentation. Every recommendation reflects current clinical guidelines and the strongest available evidence.

Systematic Laboratory Evaluation Including Ferritin

We always include serum ferritin in our telogen effluvium laboratory evaluation, not just hemoglobin or complete blood count. Iron deficiency is the most common correctable cause of telogen effluvium in women and the most commonly missed. We assess ferritin to the hair-relevant target of 70 ng/mL rather than simply to the lower limit of the laboratory reference range. We order the complete targeted panel that identifies every correctable nutritional and systemic contributor, and we review results in the context of your full clinical picture to generate a specific, actionable diagnosis.

Trichoscopy to Identify Concurrent Conditions

We perform trichoscopy at every hair loss evaluation. In telogen effluvium, trichoscopy serves two purposes: confirming the non-miniaturized follicular pattern of telogen effluvium and identifying any concurrent androgenetic alopecia that the triggering event has unmasked or accelerated. Identifying both components when present changes the management plan, because the TE component and the androgenetic component each require different management strategies and have different prognoses.

Minoxidil and PRP as Active Treatment Options

We do not limit telogen effluvium management to reassurance and nutritional correction. When active pharmacological support is appropriate, whether because of prolonged shedding, coexisting androgenetic alopecia, patient distress level, or suboptimal recovery trajectory, we offer topical and oral minoxidil bridge therapy and in-office PRP treatments to support and accelerate density recovery.

Honest Communication About Prognosis

We tell every patient with telogen effluvium clearly what the realistic recovery timeline looks like, what percentage of their density should return and when, what signs would indicate the recovery is proceeding as expected, and what would warrant a follow-up evaluation. We are honest about the distinction between typical acute telogen effluvium with an excellent prognosis and chronic telogen effluvium with a more variable but still favorable long-term outlook. Patients leave every appointment knowing exactly what to expect.

Patient Education and Support

Understanding why your hair is shedding, why it started two to three months after whatever caused it, how the hair cycle recovers, what the ferritin target means for your specific situation, and what you can do practically to support recovery reduces anxiety and improves treatment adherence. We build this education into every telogen effluvium consultation as a core component of care, not an afterthought.

Compassionate, Patient-Centered Care

Watching your hair fill the shower drain day after day, not knowing when it will stop, not knowing whether it will grow back, is genuinely distressing. Our team approaches every telogen effluvium consultation with the seriousness the patient’s experience deserves, the clinical thoroughness the condition requires, and the clear, honest communication that is the most powerful management tool available for a condition whose most feared complication, permanent hair loss, almost never occurs.

What To Expect During Treatment

Guiding You Through Evaluation and the Next Steps

Many patients who come to Connolly Dermatology for telogen effluvium have been living with months of alarming shedding, have received incomplete evaluations elsewhere, or have spent weeks searching online and concluding they may have permanent hair loss. Our evaluation is designed to provide the complete diagnostic picture and the specific, honest prognosis that transforms how patients experience the recovery period.

Before Your Appointment

Thorough preparation before your visit dramatically improves the quality of your history and the efficiency of your evaluation. Create a written timeline working backward from when shedding began: document every significant event in the 2 to 4 months before shedding started, including illnesses, medical procedures, stressful life events, dietary changes, weight changes, and any new medications. Write down every medication, supplement, vitamin, and herbal preparation you currently take and any you have started or stopped in the past 6 months. Note your obstetric history if applicable, your menstrual cycle regularity, your contraceptive history, and any perimenopausal symptoms. Document any prior laboratory work related to thyroid function, iron studies, or blood counts, and bring results if available. Photograph the amount of hair you shed in a typical shower and on your brush on a representative day, as this provides useful quantification. Bring notes on any hair loss treatments you have tried and your experience with each.

During the Evaluation

Your dermatologist conducts a thorough, timeline-oriented history review before examining your scalp and hair. The hair pull test is performed across multiple scalp regions. Trichoscopy is applied to the affected areas to characterize the follicular pattern. Blood draw orders are provided at the same visit for the complete targeted laboratory panel; results are typically available within 3 to 7 days.

After the examination, your dermatologist explains their clinical assessment, discusses which diagnosis or diagnoses are consistent with your presentation, and explains clearly which laboratory results will be most informative for guiding treatment. If telogen effluvium is the confirmed or leading diagnosis, the mechanism is explained, the expected timeline for recovery is outlined, and the specific management plan is discussed. If an identifiable trigger has already been established through history, initial management begins immediately. If the trigger is uncertain pending laboratory results, a follow-up consultation is scheduled for results review and treatment planning within one to two weeks.

After Your Laboratory Results

Your dermatologist reviews every laboratory result with you at a follow-up visit or through a coordinated communication, explaining what each result means for your hair recovery. Identified deficiencies are addressed with specific supplementation protocols and targets. Thyroid abnormalities are communicated to your primary care physician or endocrinologist with coordination of treatment. Medication triggers are discussed with the option to review alternatives with your prescribing physician. A clear, written treatment plan is provided, including every supplement or medication prescribed, its dose, the expected timeline for benefit, and the laboratory follow-up schedule to confirm rising ferritin or normalized thyroid function.

Most patients with acute telogen effluvium notice a meaningful slowing of shedding within 2 to 3 months of trigger correction and nutritional optimization, and visible density improvement within 6 months. Full density recovery in typical acute telogen effluvium occurs within 6 to 12 months. Follow-up visits at 3 and 6 months assess the recovery trajectory and confirm that laboratory parameters are reaching their targets. Patients with chronic telogen effluvium are followed at closer intervals, with treatment adjustments made based on the evolving clinical picture. Throughout the recovery period, patients have access to their care team for questions and reassurance, because the psychological burden of hair loss is highest during the months when shedding continues before visible recovery begins, and responsive communication from the clinical team during this period is a genuine component of comprehensive care.

Get Clear Answers from Connolly Dermatology

Make Informed Decisions About Your Hair Health

Telogen effluvium is the most common cause of diffuse hair shedding, one of the most treatable hair conditions, and one of the most commonly evaluated without the specific laboratory testing, detailed timeline history, and evidence-based target setting that actually produces the fastest complete recovery. The condition is not mysterious. It has a cause. That cause is identifiable in the overwhelming majority of patients through a systematic evaluation. When the cause is addressed and any nutritional deficiencies corrected to evidence-based targets, the hair grows back.

The reassurance that telogen effluvium is reversible is genuinely meaningful, but it is most useful when it is accompanied by a specific trigger identification, a targeted laboratory correction plan with defined endpoints, an honest timeline for recovery, and access to bridge pharmacological therapy when the situation warrants it. That is what a thorough dermatologic evaluation provides and what self-management with general reassurance does not.

If you are experiencing diffuse hair shedding that concerns you, whether it began after an illness, childbirth, a stressful period, a dietary change, a new medication, or with no clear explanation you can identify, a dermatology evaluation provides the complete answer your situation deserves. At Connolly Dermatology, our board-certified dermatologists offer expert evaluation with trichoscopy, comprehensive targeted laboratory assessment including ferritin, and personalized management plans that address every correctable contributor to your hair loss.

Schedule a visit with a dermatologist to get clear, informed guidance about your hair loss.